ZWI-ZW49-101
14 Dec 2022
Trial Summary
This is a first-in-human, Phase 1, multicenter, open-label, dose-escalation study to establish the maximum-tolerated dose (MTD) or recommended dosage (RD) of ZW49, the investigational agent under study, and to assess the safety and tolerability of ZW49. Eligible patients include those with locally advanced (unresectable) or metastatic HER2-expressing cancers.
Acronym:
ZWI-ZW49-101
ACTRN/NCT /ethics:
NCT03821233
Scientific title:
A Phase 1 Study of ZW49 in Patients With Locally Advanced (Unresectable) or Metastatic HER2-Expressing Cancers
Sponsor / Cooperative group:
Zymeworks Inc.
Trial & Patient Characteristics
| Cancer Type | Breast, Stomach & Oesophageal |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | Locally Advanced, Metastatic or Widespread |
| Anticipated Start Date | 2019-04-15 |
| Anticipated End Date | 2023-08-01 |
Participating Hospitals
| Hospital | Flinders Medical Centre |
|---|---|
| Clinical Trial Coordinator | Alison Richards |
| Alison.Richards@sa.gov.au | |
| Phone | 08 8206 4835 |
| Principal Investigator | Professor Chris Karapetis |
| Recruitment Status | Recruiting |